<DOC>
	<DOCNO>NCT02594267</DOCNO>
	<brief_summary>The purpose study evaluate Maximum Tolerated Dose ( MTD ) pralatrexate combination cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) regimen patient newly diagnose peripheral T-cell lymphoma ( PTCL ) .</brief_summary>
	<brief_title>A Dose-Finding Study FolotynÂ® ( Pralatrexate Injection ) Plus CHOP With Peripheral T-Cell Lymphoma ( PTCL )</brief_title>
	<detailed_description>This Phase 1 , open-label , multicenter , two-part , dose-finding , dose-escalation study . The study divide two part : Part 1 Up five sequential dose cohort enroll maximum 6 patient . Escalation pralatrexate dose , CHOP administration ( Fol-CHOP ) , continue traditional 3+3 design , determination MTD . If MTD reach , Maximum Administered Dose ( MAD ) pralatrexate combination CHOP 30 mg/m2 IV Days 1 8 21-day cycle 6 cycle . The first cohort begin three patient dose A CHOP full dose . If none first three patient experience Dose-Limiting Toxicity ( DLT ) , next three patient enrol next high dose cohort . If one first three patient first cohort experience DLTs , additional three patient enrol cohort . If 2 3 first 3 patient experience DLTs , MTD find . For cohort 2 , 3 , 4 , 5 , If none first three patient experience DLT , next three patient enrol next high dose cohort . If one first three patient first cohort experience DLTs , additional three patient enrol cohort . If 2 3 first 3 patient experience DLTs , previous cohort consider MTD additional 10 patient enrol dose Part 2 study . Part 2 Once MTD Fol-CHOP regimen establish Part 1 study , additional 10 patient treat MTD ( MAD MTD reach ) confirm tolerability . Additionally , PK establish MTD pralatrexate , administer CHOP full dose , evaluate 10 patient .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<criteria>1 . Age 18 year 2 . Adequate hematologic , hepatic , renal function 3 . Histologically confirm , new diagnosis PTCL 4 . Eligible CHOP regimen 5 . Measurable disease base Cheson 2007 criterion 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 7 . Willing perform least two method contraception 8 . Negative pregnancy test female childbearing potential . 1 . Active concurrent malignancy ( except non melanoma skin cancer carcinoma situ cervix ) life threaten disease . If history prior malignancy life threaten disease , patient must disease free least 5 year . 2 . Congestive heart failure Class III/IV accord New York Heart Association ( NYHA ) Functional Classification . 3 . Uncontrolled hypertension 4 . Central nervous system ( CNS ) metastases . 5 . Active uncontrolled infection , underlie medical condition , serious illness would impair ability patient receive protocol treatment 6 . Major surgery within 30 day prior enrollment . 7 . Use investigational drug , biologics , device within 30 day prior study treatment . 8 . Previous exposure pralatrexate . 9 . Pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PTCL</keyword>
	<keyword>Peripheral T-Cell Lymphoma</keyword>
	<keyword>Folotyn</keyword>
	<keyword>Pralatrexate</keyword>
	<keyword>CHOP</keyword>
</DOC>